INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Claude Bernard University Lyon 1
Villeurbanne, FranciaPublicaciones en colaboración con investigadores/as de Claude Bernard University Lyon 1 (32)
2024
-
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study
Haematologica, Vol. 109, Núm. 3, pp. 867-876
-
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine
The Lancet Respiratory Medicine, Vol. 12, Núm. 4, pp. 305-322
2023
-
Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors
Hematological Oncology, Vol. 41, Núm. 4, pp. 631-643
-
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Blood
-
Microglial phagocytosis dysfunction in stroke is driven by energy depletion and induction of autophagy
Autophagy, Vol. 19, Núm. 7, pp. 1952-1981
-
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
American Journal of Hematology, Vol. 98, Núm. 11, pp. 1699-1710
2022
-
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 242-251
-
Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Journal of Clinical Oncology
2021
-
Common gene variants within 3′-untranslated regions as modulators of multiple myeloma risk and survival
International Journal of Cancer, Vol. 148, Núm. 8, pp. 1887-1894
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma
European Journal of Cancer, Vol. 157, pp. 132-139
-
Validation of the Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales in French, Spanish, and German Languages, among a Sample of Opioid Users
European Addiction Research, Vol. 27, Núm. 5, pp. 326-331
2020
-
Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium
Blood Cancer Journal, Vol. 10, Núm. 7
-
Procedural and Short-Term Results With the New Watchman FLX Left Atrial Appendage Occlusion Device
JACC: Cardiovascular Interventions, Vol. 13, Núm. 23, pp. 2732-2741
-
Prognostic gene expression signature for high-grade serous ovarian cancer
Annals of Oncology, Vol. 31, Núm. 9, pp. 1240-1250
2019
-
Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma
Journal of Clinical Oncology
2018
-
Defining the species Micromonospora saelicesensis and Micromonospora noduli under the framework of genomics
Frontiers in Microbiology, Vol. 9, Núm. JUN
-
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204
-
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
The Lancet Haematology, Vol. 5, Núm. 8, pp. e359-e367
2017
-
Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2473-2481